Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab after CABG in acute coronary syndrome
ChiCTR2500112714Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in coronary arteriosclerosis and acute coronary syndrome (ACS) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Major Adverse Cardiac Events (MACE). Started Nov 2025; status: recruiting.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2500112714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112714.